Literature DB >> 21913349

Safety and efficacy of combined trabeculectomy for primary angle closure glaucoma with persistent ocular hypertension.

Xiaojie He1, Runcai Ye, Fei Xu, Yizong Yuan.   

Abstract

PURPOSE: To investigate the safety and efficacy of combined trabeculectomy for primary acute angle closure glaucoma with persistent ocular hypertension.
METHODS: A total of 36 patients (40 eyes) with primary acute angle closure glaucoma,who were treated with combined trabeculectomy in the Ophthalmology unit of our hospital,were selected. Before the procedure,patients were assigned to an ocular hypertension group (≥ 40 mmHg) or a control group (<40 mmHg) based on intraocular pressure.These two groups were followed for one year, and compared for post-operative visual acuity, intraocular pressure, filtering bleb, anterior chamber depth, and the occurrence of complications.
RESULTS: At 1 week, 6 months, and 12 months after the procedure, intraocular pressure was controlled in both the ocular hypertension group and the control group, without significant differences between the two groups (P>0.05). At 1 week, 6 months, and 12 months after the procedure, all of the patients, in both groups,had improved in terms of visual acuity, with a significant difference before and after the procedure for the ocular hypertension group (P<0.05). After follow-up at 12 months, the two groups presented no statistically significant differences in anterior chamber depth, filtering bleb survival, or the incidence of post-operative complications (P>0.05 for all).
CONCLUSION: It is feasible,safe,and effective to perform combined trabeculectomy on patients with primary acute angle closure glaucoma complicated by persistent ocular hypertension.

Entities:  

Mesh:

Year:  2011        PMID: 21913349     DOI: 10.3969/j.issn.1000-4432.2011.03.008

Source DB:  PubMed          Journal:  Eye Sci


  1 in total

1.  Small-incision phacotrabeculectomy versus phacoemulsification in refractory acute primary angle closure with cataract.

Authors:  Xu Hou; Dan Hu; Zhili Cui; Jian Zhou; Li Cai; Yusheng Wang
Journal:  BMC Ophthalmol       Date:  2015-07-29       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.